TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26474292

Group type: EXPERIMENTAL
Intervention: Weighted endurance exercise (LC) with EAA supplementation (10 g EAA, 3.6 g leucine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Conventional endurance exercise (CE) with EAA supplementation (10 g EAA, 3.6 g leucine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Weighted endurance exercise (LC) with control drink (non-nutritive)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional endurance exercise (CE) with control drink (non-nutritive)
Number of subjects: 40
Study: 26474455

Group type: EXPERIMENTAL
Intervention: Genetic score based on five SNPs (PSMB10, TNFRSF10D, PSMB2, PPARD, CYP26B1)
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: CML-risk-allele score
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Risk alleles from haplotype analysis
Number of subjects: 437

Group type: COMPARATOR
Intervention: Single SNP association analysis
Number of subjects: 437
Study: 26474521

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by local excision (capecitabine 725 mg/m² twice daily, oxaliplatin 50 mg/m², radiation 50.4 Gy total)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy followed by local excision
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Surgery after neoadjuvant chemoradiotherapy
Number of subjects: 79
Study: 26474734

Group type: EXPERIMENTAL
Intervention: Bowel occult microscopic endometriosis (BOME) present
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bowel occult microscopic endometriosis (BOME) absent
Number of subjects: 103
Study: 26474738

Group type: EXPERIMENTAL
Intervention: Resting Heart Rate (RHR) groups
Number of subjects: 19200

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 19200

Group type: EXPERIMENTAL
Intervention: AAA incidence
Number of subjects: 19200
Study: 26474775

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (35% fat; 22% from monounsaturated fatty acids)
Number of subjects: 642

Group type: COMPARATOR
Intervention: Low-fat diet (<28% fat)
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 642
Study: 26475140

Group type: EXPERIMENTAL
Intervention: AMT-PET scanning
Number of subjects: 21
Study: 26475205

Group type: EXPERIMENTAL
Intervention: FFRCT (Fractional Flow Reserve Computed Tomography)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: FFRCT
Number of subjects: 584
Study: 26475445

Group type: EXPERIMENTAL
Intervention: CYD-TDV (administered at 0, 6, and 12 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term surveillance from phase 3 studies and phase 2b study
Number of subjects: 0
Study: 26475577

Group type: EXPERIMENTAL
Intervention: Suicidal behaviour prior to first presentation of psychosis and during a 3-year follow-up
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Severity of depressive symptoms and cannabis use
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 'Early' attempters characteristics
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 'Late' attempters characteristics
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Early intervention programmes targeting phase-specific risk factors
Number of subjects: 397
Study: 26475726

Group type: EXPERIMENTAL
Intervention: Fluticasone, Azithromycin, and Montelukast (FAM)
Number of subjects: 36
Study: 26476290

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir (25/150/100mg once daily) and dasabuvir (250mg twice daily) for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Number of subjects: 60
Study: 26476398

Group type: EXPERIMENTAL
Intervention: Native T1 (MOLLI)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Native T1 (ShMOLLI)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: T2 relaxation times
Number of subjects: 34

Group type: COMPARATOR
Intervention: T2-ratio
Number of subjects: 34

Group type: COMPARATOR
Intervention: EGEr
Number of subjects: 34

Group type: COMPARATOR
Intervention: LGE
Number of subjects: 34

Group type: COMPARATOR
Intervention: LLC
Number of subjects: 34

Group type: COMPARATOR
Intervention: ECV MOLLI
Number of subjects: 34

Group type: COMPARATOR
Intervention: ECV ShMOLLI
Number of subjects: 34

Group type: COMPARATOR
Intervention: Longitudinal strain
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined native parameters (T1, T2, and longitudinal strain)
Number of subjects: 34
Study: 26476503

Group type: EXPERIMENTAL
Intervention: Echocardiography (echo)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Delayed enhancement cardiac magnetic resonance (DE-CMR)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Noncontrast echocardiography
Number of subjects: 201

Group type: COMPARATOR
Intervention: Contrast echocardiography
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Echocardiography-based apical wall motion score
Number of subjects: 201
Study: 26477337

Group type: EXPERIMENTAL
Intervention: Adrenalectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 41
Study: 26477497

Group type: EXPERIMENTAL
Intervention: New AMH immunoassay method (Ansh Labs)
Number of subjects: 45
Study: 26477820

Group type: EXPERIMENTAL
Intervention: Presence of minor allele rs1050851 in NFKBIA gene
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Presence of minor allele rs2233417 in NFKBIA gene
Number of subjects: 401

Group type: COMPARATOR
Intervention: Presence of minor alleles in NFKBIA SNPs
Number of subjects: 401
Study: 26478682

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 52
Study: 26479222

Group type: EXPERIMENTAL
Intervention: Antipsychotic dosing regimen, specific details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, specific details not available
Number of subjects: 0
Study: 26479487

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for treatment-resistant MDD and BPII depression
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for treatment-resistant MDD
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for treatment-resistant BPII depression
Number of subjects: 1098
Study: 26481067

Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following total or sub-total gastrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following pancreatic resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following liver resection without hepatico-intestinal anastomosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic intra-abdominal drainage following rectal resection
Number of subjects: 0
Study: 26481843

Group type: EXPERIMENTAL
Intervention: Nonculprit fibroatheromas (FAs) classified as proximal (<20 mm), mid (20 to 40 mm), and distal (>40 mm) based on distance from the ostium to the maximum necrotic core site.
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Distance from the ostium to the maximum necrotic core site (per mm)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Plaque burden (per 10%)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Vessel area (per mm²)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Calcium presence
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Right coronary artery location
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Vessel area
Number of subjects: 697
Study: 26481915

Group type: EXPERIMENTAL
Intervention: Heart-focused anxiety (HFA)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: General anxiety
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Heart-focused anxiety predictors
Number of subjects: 110
Study: 26482301

Group type: EXPERIMENTAL
Intervention: Rifabutin treatment
Number of subjects: 35
Study: 26482312

Group type: EXPERIMENTAL
Intervention: Telavancin (10 mg/kg/day for CLCR >50 ml/min; 7.5 mg/kg/day for CLCR 30-49 ml/min)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vancomycin (historical control)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 78
Study: 26482357

Group type: EXPERIMENTAL
Intervention: Interventions at individual, relational, community, and institutional levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research on personal, situational, and socio-cultural factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public health recognition of violence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions suggested in the review
Number of subjects: 0
Study: 26482376

Group type: EXPERIMENTAL
Intervention: Sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days) in addition to standard therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydration (same volume per day)
Number of subjects: 80
Study: 26482769

Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 0
Study: 26482895

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD) via endovascular radiofrequency ablation (RFA) of the renal arteries, with continued full-dose antihypertensive therapy (4.1 drugs) including diuretics.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD)
Number of subjects: 60
Study: 26482997

Group type: EXPERIMENTAL
Intervention: Nellix EndoVascular Aneurysm Sealing system
Number of subjects: 150
Study: 26483003

Group type: EXPERIMENTAL
Intervention: Misago stent
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Misago stent (U.S. patients)
Number of subjects: 261
Study: 26483004

Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Stent Graft System (main stent graft diameter 28 to 42 mm, branch stent graft diameter 10 to 14 mm)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Valiant Mona LSA Stent Graft System
Number of subjects: 9
Study: 26483097

Group type: EXPERIMENTAL
Intervention: HeartMate II (HMII) LVAD support
Number of subjects: 200

Group type: COMPARATOR
Intervention: Optimal medical management (OMM)
Number of subjects: 200
Study: 26483098

Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) placement
Number of subjects: 0
Study: 26483108

Group type: EXPERIMENTAL
Intervention: Statin-based LDL-C lowering therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26483193

Group type: EXPERIMENTAL
Intervention: Chiropractic primary care (Sample A)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Gainfully employed population (Sample B)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Secondary care rehabilitation clinic (Sample C)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Secondary care clinics (Sample D)
Number of subjects: 480
Study: 26483516

Group type: EXPERIMENTAL
Intervention: Telaprevir-based therapy (750 mg every 8 hours, 1125 mg if on efavirenz) plus Peg-IFNα2a (180 μg/week) and ribavirin (800 mg/day) for 12 weeks, followed by Peg-IFNα2a and ribavirin alone for 12 or 36 weeks depending on patient type.
Number of subjects: 162

Group type: COMPARATOR
Intervention: Telaprevir-based therapy
Number of subjects: 162
Study: 26485680

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 29
Study: 26486356

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 4 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (OLM)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 4 months in OOM group
Number of subjects: 46
Study: 26486517

Group type: EXPERIMENTAL
Intervention: Tariquidar (2 mg/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tariquidar in combination with docetaxel
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tariquidar in combination with vinorelbine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tariquidar
Number of subjects: 29
Study: 26486974

Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/day) for 180 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (healthy normolipidemic age-matched nonobese males), n = 12
Number of subjects: 12
Study: 26487230

Group type: EXPERIMENTAL
Intervention: Endosonography (EUS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: White Light Endoscopy (WLE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy (CLE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Expert evaluation of CLE
Number of subjects: 24
Study: 26487580

Group type: EXPERIMENTAL
Intervention: Metabolic phenotyping of plasma
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Independent validation cohort
Number of subjects: 134
Study: 26487748

Group type: EXPERIMENTAL
Intervention: Lower limit of normal criterion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Conventional cutoff values (80% predicted value and FEV1/FVC <0.7)
Number of subjects: 164
Study: 26488168

Group type: EXPERIMENTAL
Intervention: School-based health promotion program
Number of subjects: 30
Study: 26488192

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Axillary radiotherapy (ART)
Number of subjects: 1425
Study: 26488691

Group type: EXPERIMENTAL
Intervention: Total knee replacement followed by 12 weeks of nonsurgical treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsurgical treatment alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total knee replacement
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 100
Study: 26488758

Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (specific dosage not mentioned)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5 Gy irradiation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Gene modulation (FAS modulation)
Number of subjects: 32
Study: 26489933

Group type: EXPERIMENTAL
Intervention: Model with delay in TF recovery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Model without delay in TF recovery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Model using TF with additional TI and PCR data
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zero-inflated truncated normal observation model
Number of subjects: 24
Study: 26490042

Group type: EXPERIMENTAL
Intervention: Enhanced MRI set-up and prolonged Holter-ECG monitoring
Number of subjects: 475

Group type: COMPARATOR
Intervention: Routine diagnostic care (including stroke unit monitoring for at least 24 h, echocardiography, and ultrasound of brain-supplying arteries)
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Enhanced MRI approach and prolonged ECG monitoring
Number of subjects: 475
Study: 26490100

Group type: EXPERIMENTAL
Intervention: Osmolarity equation: osmolarity=1.86×(Na++K+)+1.15×glucose+urea+14 (all measured in mmol/L)
Number of subjects: 595

Group type: COMPARATOR
Intervention: 39 osmolarity equations calculated using serum indices from the same blood draw as directly measured osmolality
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Best equation identified
Number of subjects: 595
Study: 26490103

Group type: EXPERIMENTAL
Intervention: Agalsidase-beta (1 mg/kg/2 weeks) with antiproteinuric therapy (ACE inhibitors or ARBs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (patients not achieving UPCR goal)
Number of subjects: 24
Study: 26490491

Group type: EXPERIMENTAL
Intervention: Energy expenditure (EE) measured by doubly labeled water before and during cycling (17 ± 1 MJ/d before vs 30 ± 2 MJ/d during; P < 0.001)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Energy intake (EI) recorded during cycling (25 ± 1 MJ/d)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Body fat change measured (-2.2 ± 0.7 kg; P = 0.02)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fat-free mass change measured (2.5 ± 0.6 kg; P = 0.01)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hunger ratings recorded twice daily (both P = 0.02)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fullness ratings recorded (P = 0.04)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of insulin increased by 120% ± 15% (P = 0.02)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of glucagon-like peptide 1 (GLP-1) increased by 60% ± 20% (P < 0.01)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fasting plasma concentrations of Polypeptide YY(3-36) increased by 80% ± 30% (P < 0.02)
Number of subjects: 6
Study: 26490495

Group type: EXPERIMENTAL
Intervention: Excessive gestational weight gain (GWG)
Number of subjects: 302
Study: 26490566

Group type: EXPERIMENTAL
Intervention: Light physical activity
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Moderate physical activity (MPA)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Participants with healthy CRF
Number of subjects: 54
Study: 26490645

Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA)
Number of subjects: 25
Study: 26491110

Group type: EXPERIMENTAL
Intervention: Clinical risk score based on age, sex, peak aortic velocity (Vmax), high-sensitivity troponin I concentration, and electrocardiographic strain pattern.
Number of subjects: 147
Study: 26491799

Group type: EXPERIMENTAL
Intervention: Erythropoietin administration and transfusion threshold
Number of subjects: 200
Study: 26492842

Group type: EXPERIMENTAL
Intervention: Reflux alone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of phonation and reflux events
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Antecedent phonation and reflux
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Reflux events
Number of subjects: 17
Study: 26492847

Group type: EXPERIMENTAL
Intervention: Lactulose challenge test (25 g lactulose in a liquid breakfast of 400 mL Nutridrink)
Number of subjects: 100
Study: 26492921

Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF) with atropine (1 mg bolus 45 min before MSF + 80 ng·kg(-1)·min(-1) for 2 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atropine + clamp + MSF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MSF
Number of subjects: 10
Study: 26493200

Group type: EXPERIMENTAL
Intervention: High-definition endoscopy with digital chromoendoscopy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High-definition endoscopy with digital chromoendoscopy (high-confidence predictions)
Number of subjects: 224
Study: 26493637

Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 19
Study: 26493661

Group type: COMPARATOR
Intervention: Household disposable income quintiles (1st quintile as control)
Number of subjects: 100534
Study: 26493785

Group type: EXPERIMENTAL
Intervention: Baseline cfDNA concentration (highest tertile)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Increased baseline cfDNA concentration
Number of subjects: 218

Group type: COMPARATOR
Intervention: cfDNA concentration
Number of subjects: 218
Study: 26493933

Group type: EXPERIMENTAL
Intervention: TOPAS system (transobturator posterior anal sling)
Number of subjects: 152
Study: 26493938

Group type: EXPERIMENTAL
Intervention: Blood eosinophil counts greater than 400 cells per μL
Number of subjects: 130248

Group type: COMPARATOR
Intervention: Blood eosinophil counts of 400 cells per μL or less
Number of subjects: 130248
Study: 26494259

Group type: EXPERIMENTAL
Intervention: cobas(®) EGFR Mutation Test
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BEAMing digital PCR
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Droplet Digital™ PCR
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: therascreen™ EGFR amplification refractory mutation system assay
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Multiple platforms
Number of subjects: 110
Study: 26494395

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study: 26495926

Group type: EXPERIMENTAL
Intervention: Moist snuff consumers (MSC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Smokers (SMK)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-tobacco consumers (NTC)
Number of subjects: 3
Study: 26495947

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) using ClearPoint interventional MRI-guided methodology
Number of subjects: 26
Study: 26496767

Group type: EXPERIMENTAL
Intervention: Pegvisomant-primed glucagon stimulation test (PegV-GST)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pegvisomant (single dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glucagon stimulation test (GST)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT)
Number of subjects: 10
Study: 26497081

Group type: EXPERIMENTAL
Intervention: Simeprevir plus sofosbuvir (12 weeks, up to 16 weeks); 169 patients received ribavirin
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Simeprevir plus sofosbuvir with ribavirin
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Simeprevir plus sofosbuvir
Number of subjects: 836
Study: 26497198

Group type: EXPERIMENTAL
Intervention: Decitabine 5 mg/m(2)/day for 5 consecutive days with 4-week intervals, individualized doses for Cycles 2 to 4 based on pharmacokinetic-pharmacodynamic modeling.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Decitabine (individualized doses for Cycles 2 to 4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Initial doses for cohorts 2 to 5 were 4, 5, 5.5, and 5 mg/m(2)/day, respectively; median maintenance dose was 7 mg/m(2)/day.
Number of subjects: 15
Study: 26497302

Group type: EXPERIMENTAL
Intervention: Multifungal DNA-microarray and Aspergillus specific PCR
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multifungal DNA-microarray
Number of subjects: 133